Breaking News Instant updates and real-time market news.

ENDP

Endo

$4.86

0.05 (1.04%)

16:18
11/04/19
11/04
16:18
11/04/19
16:18

Endo announces CEO Paul Campanelli to retire

Endo announced that Paul Campanelli, President and CEO has notified the Board of Directors of his intention to retire and the Board is implementing its CEO succession plan. Campanelli has been appointed Chairman of the Board effective immediately and will also continue to serve as President and CEO until his successor is appointed. Roger Kimmel, who has served as Chairman of the Board, has been appointed Senior Independent Director. Kimmel replaces Dr. Sharad Mansukani, who is resigning from the Board due to other commitments, including his recent appointment as chairman of the board of another company. The Board is launching a process to identify Campanelli's successor. Campanelli will be actively involved in that process and will help facilitate a smooth transition. In addition, he will continue to serve as Chairman of the Board following the appointment of his successor.

  • 05

    Nov

ENDP Endo
$4.86

0.05 (1.04%)

07/15/19
MSCO
07/15/19
DOWNGRADE
Target $3
MSCO
Underweight
Endo downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Endo International to Underweight from Equal Weight and cut his price target for the shares to $3 from $8.
07/15/19
MSCO
07/15/19
DOWNGRADE
MSCO
Underweight
Endo, Teva downgraded to Underweight on underappreciated risks at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Endo International (ENDP) and Teva Pharmaceutical (TEVA), both to Underweight from Equal Weight, cut his price target on Endo shares to $3 from $8 and lowered his price target for Teva shares to $6 from $16. In the wake of Amneal's (AMRX) recent 28% EBITDA guidance cut, Risinger noted that Amneal faces company-specific challenges but also said he is concern about potentially worsening U.S. competitive pricing pressure. He is worried that Endo and Teva both face "underappreciated" risks from buying group pressure being worse than expected, increasing competition among generic manufacturers and the fact that opioid litigation is "just getting started" with thousands of lawsuits having been filed. Risinger also cut his earnings estimates for Mylan (MYL) lowered his price target on its shares to $22 from $32, though he maintains an Overweight rating on that generic drugmaker, citing low valuation and the potential for corporate action. Risinger additionally lowered his price target on Amneal shares to $4 from $12.
07/15/19
07/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) and Endo (ENDP) downgraded to Underweight from Equal Weight at Morgan Stanley. 2. Marriott (MAR) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation. 3. General Electric (GE) downgraded to Neutral from Buy at UBS with analyst Damian Karas saying that a "notable" decline in interest rates and the continued weakness in the power market combine toward a "more balanced" upside with downside. 4. WageWorks (WAGE) downgraded to Hold from Buy at Stifel with analyst David Grossman saying he does not envision a competing takeover offer for the company. 5. L Brands (LB) downgraded to Neutral from Buy at Citi with analyst Paul Lejuez saying his former view on the stock was based on the belief that a Victoria's Secret turnaround could be successful if the brand adopted a more inclusive approach. However, with management slow to implement meaningful change, and "cultural norms shifting away from them," it may be "too little too late" for a meaningful turnaround at Victoria's Secret. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Neutral
Endo assumed with a Neutral at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Endo International with a Neutral rating and a $2-$4 fair value range. The analyst noted that the upcoming opioid litigation, which Endo has significant exposure to, will be hard to call, but he estimates $3B-$4B in opioid liability paid out over ten years, and believes the risks are already reflected in the stock.

TODAY'S FREE FLY STORIES

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

07:56
12/07/19
12/07
07:56
12/07/19
07:56
Hot Stocks
AbbVie announces data from Phase 2 lymphocytic leukemia study »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:51
12/07/19
12/07
07:51
12/07/19
07:51
Hot Stocks
Janssen announces initial results from Phase 1b/2 multiple myeloma study »

Janssen Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

XBIT

XBiotech

$11.11

0.1 (0.91%)

, JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

07:46
12/07/19
12/07
07:46
12/07/19
07:46
Hot Stocks
XBiotech sells bermekimab to Janssen for $750M plus potential milestones »

XBiotech (XBIT) announced…

XBIT

XBiotech

$11.11

0.1 (0.91%)

JNJ

Johnson & Johnson

$140.36

0.79 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 21

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.